

RANBAXY

Trusted medicines. Healthier lives

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA

PHONE: +91-124-4135000 FAX: +91-124-4106490

E-mail: secretarial@ranbaxy.com

BY FAX/EMAIL/COURIER

October 21, 2013

TO : STOCK EXCHANGES

Dear Sirs,

Enclosed please find Press Release dated October 21, 2013 titled “(i) Ranbaxy receives CDSCO approval to market SynriamTM in India for treatment of malaria caused by *Plasmodium vivax* parasite (ii) Single treatment for both *Plasmodium vivax* and *Plasmodium falciparum* malaria and (iii) Permission received to conduct Phase III clinical trials for pediatric formulation” which is being issued by the Company today.

This is for your information please.

Thanking you,

Yours faithfully,
for RANBAXY LABORATORIES LTD.


(S.K. PATAWARI)
COMPANY SECRETARY

Encl. : As above.

RANBAXY

Trusted medicines. Healthier lives

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA

PHONE: +91-124-4135000 FAX: +91-124-4106490

E-mail: secretarial@ranbaxy.com**Press Release**

Ranbaxy receives CDSCO approval to market Synriam™ in India for treatment of malaria caused by *Plasmodium vivax* parasite

Single treatment for both *Plasmodium vivax* and *Plasmodium falciparum* malaria

Permission received to conduct Phase III clinical trials for pediatric formulation

Gurgaon, India, October 21, 2013: Ranbaxy Laboratories Limited (Ranbaxy) today announced that the company has received approval from the Central Drugs Standard Control Organisation (CDSCO), Government of India to manufacture and market Synriam™ (arterolane maleate and piperaquine phosphate tablet 150+750 mg) in India for the treatment of uncomplicated malaria in adults caused by *Plasmodium vivax* parasite.

Phase III clinical trials for the drug conducted in India, successfully demonstrated the efficacy and tolerability of Synriam™ as comparable to chloroquine.

Last year on World Malaria Day, April 25, Ranbaxy had launched India's first new drug, Synriam™ for the treatment of uncomplicated *Plasmodium falciparum* malaria in India. Since its launch, Synriam™ has successfully treated around one million patients.

The company has also received permission to conduct Phase III clinical trials for the pediatric formulation in pediatric patients of uncomplicated *Plasmodium falciparum* malaria.

Commenting on the approval, Arun Sawhney, CEO & Managing Director, Ranbaxy, said, "Synriam™ is a new age cure for malaria and is fast emerging as the preferred option in the hands of doctors. This approval makes Synriam™ one of the few therapies in the world that successfully treats both, *Plasmodium vivax* and *Plasmodium falciparum* malaria. Ranbaxy remains committed in its fight against malaria and we are making all efforts to make this new therapy accessible to patients around the world."

Ranbaxy is working to make this new treatment available in African, Asian and South American markets where malaria is rampant. The company has filed New Drug Applications (NDAs) for marketing Synriam™ in some African countries and will be filing more applications during the year. Once approved, the product will be launched in these markets.



RANBAXY LABORATORIES LIMITED

HEAD OFFICE: 12TH FLOOR, DEVTA TOWER, 6, NEHRU PLACE, NEW DELHI - 110019

REGISTERED OFFICE: A-41, INDUSTRIAL AREA PHASE VIII-A, SAHIBZADA AJIT SINGH NAGAR, MOHALI - 160071 (PUNJAB)

WEBSITE: <http://www.ranbaxy.com>

RANBAXY

Trusted medicines. Healthier lives

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA

PHONE: +91-124-4135000 FAX: +91-124-4106490

E-mail: secretarial@ranbaxy.com

Synriam™ provides quick relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95%. It conforms to the recommendations of the World Health Organization (WHO) for using combination therapy in malaria.

As the dosage regimen for Synriam™ is simple, it leads to better compliance. A patient is required to take just one tablet per day, for three days, compared to other medicines where two to four tablets are required to be taken, twice daily, for three or more days. The drug is also independent of dietary restrictions for fatty foods or milk, as is the case with older anti-malarial therapies. Since Synriam™ has a synthetic source, unlike artemisinin-based drugs, production can be scaled up whenever required and a consistent supply can be maintained at a low cost.

According to the World Malaria Report 2012 published by WHO, India sees about 1.3 million confirmed cases of malaria each year, about 50% of which are caused by *Plasmodium vivax*, the second most important species after *Plasmodium falciparum*. Worldwide, 40% of total malaria burden globally is due to *Plasmodium vivax*, which shows the vast potential of Synriam™ in India and globally.

Traditional drugs are proving ineffective against the deadly malarial parasite because it has progressively acquired marked resistance to available drugs. Availability of plant based Artemisinin, a primary ingredient in established anti-malarial therapies is finite and unreliable. This leads to price fluctuations and supply constraints, which is not the case with a synthetic drug like Synriam™.

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 150 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.

Our Philosophy: Quality and Patients First.



RANBAXY LABORATORIES LIMITED

HEAD OFFICE: 12TH FLOOR, DEVIKA TOWER, 6, NEHRU PLACE, NEW DELHI - 110019

REGISTERED OFFICE: A-41, INDUSTRIAL AREA PHASE VIII-A, SAHIBZADA AJIT SINGH NAGAR, MOHALI - 160071 (PUNJAB)

WEBSITE: <http://www.ranbaxy.com>

RANBAXY

Trusted medicines. Healthier lives

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDIA
PHONE: +91-124-4135000 FAX: +91-124-4106490
E-mail: secretarial@ranbaxy.com

For further information please contact:

Koji Ogawa
Head - Corporate Services
email: koji.ogawa@ranbaxy.com
Tel: +91-124-4135620

Krishnan Ramalingam
General Manager – Global Corporate Communications
email: krishnan.ramalingam@ranbaxy.com
Mobile: 9810042540

Gaurav Chugh
Senior Manager – Global Corporate Communications
email: gaurav.chugh@ranbaxy.com
Mobile: 9810471414

